CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later
Ten-year follow-up of the trial that established combination checkpoint blockade shows median survival over six years with nivolumab plus ipilimumab and a plateau in the survival curve consistent with cure.
CheckMate 067 randomised 945 patients with previously untreated advanced melanoma to nivolumab plus ipilimumab, nivolumab alone, or ipilimumab alone (Larkin et al., NEJM 2015). The final 10-year report (minimum follow-up 10 years) showed median overall survival of 71.9 months with the combination, 36.9 months with nivolumab and 19.9 months with ipilimumab; 10-year OS was about 43%, 37% and 19%, and melanoma-specific survival 52%, 44% and 23%. Survival curves plateaued after about three years, and most patients alive at 10 years had been off treatment for years without further therapy. Grade 3-4 treatment-related adverse events occurred in nearly 60% with the combination versus roughly a quarter with either monotherapy, but no new late safety signals emerged. Ipilimumab plus nivolumab produced its largest relative benefit in BRAF-mutant and PD-L1-negative subgroups, though the trial was not powered to compare the combination with nivolumab alone.
- 945 previously untreated advanced melanoma patients; nivolumab + ipilimumab vs nivolumab vs ipilimumab (1:1:1).
- Median OS 71.9 vs 36.9 vs 19.9 months; 10-year OS about 43% vs 37% vs 19%.
- 10-year melanoma-specific survival 52% vs 44% vs 23%; median not reached for the combination.
- Survival curves plateau from around year 3; most long-term survivors are off therapy.
- Grade 3-4 treatment-related adverse events nearly 60% with the combination vs about a quarter with monotherapy; no new late toxicities.
Before 2011 median survival in metastatic melanoma was under a year; this trial shows that roughly half of patients treated with combination checkpoint blockade are now long-term survivors, effectively cured. It anchors first-line treatment of advanced melanoma and sets the benchmark for every new regimen, including nivolumab-relatlimab. The combination's toxicity means nivolumab alone or newer doublets remain reasonable for some patients.
- The trial was not designed or powered for a formal comparison of the combination against nivolumab alone; that difference is descriptive.
- Toxicity of the combination is high and around 40% stopped treatment early for adverse events, though many still benefited.
- Subsequent therapies (including crossover-like use of the other agents) influence long-term survival.
- Results are in melanoma; long-term cure fractions in other cancers are lower.
Checkpoint inhibitors are now given to hundreds of thousands of patients a year, many in community clinics and emergency departments, so a common, explicit playbook for their autoimmune side effects saves lives. The guideline standardised when to stop, when to give steroids and when to escalate, and made multidisciplinary toxicity teams routine. It does not remove the judgement needed for rare events or for patients whose cancer is responding.
This paper launched the immunotherapy era. It was the first randomised evidence that taking a brake off the immune system could extend life in a solid cancer, and it introduced clinicians to immune-related adverse events and to responses that arrive late or after apparent progression. Ipilimumab alone has since been superseded by PD-1 antibodies and combinations, but every checkpoint programme traces back to this result.